The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V03 | All other therapeutic products | |
| 3 | V03A | All other therapeutic products | |
| 4 | V03AF | Detoxifying agents for antineoplastic treatment | |
| 5 | V03AF10 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 30 mg |
| Active Ingredient | Description | |
|---|---|---|
| Sodium levofolinate |
Sodium levofolinate is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Sodium levofolinate does not require reduction by dihydrofolate reductase to participate in reactions utilizing folates as a source of “one-carbon” moieties. Administration of levoleucovorin counteracts the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
